ArticleNAR cancer2026
Persistent interferon signaling and clonal expansion mark early events in DNA methylation damage-induced liver cancer.
Abstract read
In one paragraph
Article in NAR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early life exposure to N-nitrosamine drives genotoxicity, mutagenesis, and tumorigenesis in DNA repair-deficient mice.Nature communications · 2026Article
Corrections and comments
- Update of
Authors and funding
24 authors.
Lee J PribylDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0003-0209-7814
Jennifer E KayDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0001-5891-0689
Joshua J CorriganDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0009-0006-6252-4960
Lindsay B VolkDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0001-8472-3836
Monét NoralesDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Norah A OwitiDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Evan A KowalDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Ishwar N KohaleDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Ilana S NazariDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Matilda R SwansonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Aimee C MoiseDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Duanduan MaDavid H. Koch Institute for Integrative Cancer Research, Bioinformatics and Computing Facility of Swanson Biotechnology Center, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Stuart S LevineBioMicro Center, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Emily M MichelsenDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Robert G CroyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Timothy RaganTissueVision, Inc., Newton, MA 02458, United States.
Dorothea K TorousLitron Laboratories, Rochester, NY 14623, United States.
Svetlana L AvlasevichLitron Laboratories, Rochester, NY 14623, United States.
Stephen D DertingerLitron Laboratories, Rochester, NY 14623, United States.
Sebastian E CarrascoLaboratory of Comparative Pathology, Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Rockefeller University, New York, NY 10065, United States.
Leona D SamsonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
John M EssigmannDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0002-2196-5691
Forest M WhiteDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0002-1545-1651
Bevin P EngelwardDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.ORCID 0000-0003-4322-3573
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTOXICOLOGY CORE UNITP30ES002109 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI NILES, JACQUIN C · 1985 to 2020
$25.6MThe MIT Superfund Research Program: A Systems Approach for the Protection of Human Health from Hazardous ChemicalsP42ES027707 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Stuart S Levine · 2017 to 2026
$22.2MTRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1MNCI NIH HHS P30 CA008748NIEHS NIH HHS P30 ES002109NIEHS NIH HHS P42 ES027707NIEHS NIH HHS T32 ES007020
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, HepatocellularDNA DamageDNA MethylationInterferonsLiver NeoplasmsAnimalsDimethylnitrosamineDNA Modification MethylasesDNA Repair EnzymesMiceMice, KnockoutSignal TransductionTumor Suppressor ProteinsDimethylnitrosamineDNA Modification MethylasesDNA Repair EnzymesInterferonsMGMT protein, mouseTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.